Comment from IQVIA

Summary: IQVIA, a global life sciences services company, supports the draft guidance while recommending specific improvements to clarify expectations for natural history studies, patient-focused drug development, and staged CMC planning. They advocate for greater specificity regarding data quality, the inclusion of patient-reported outcomes, and transparent data sharing in ultra-rare disease contexts.